First Manhattan’s Lexicon Pharmaceuticals LXRX Stock Holding History

First Manhattan’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,079	Closed	-$5K	–	1631
2021 Q3	$5K	Hold	1,079	–	–	﹤0.01%	1390
2021 Q2	$4K	Buy	+1,079	New	+$5.2K	﹤0.01%	1434
2019 Q3	–	Sell	-2,949,979	Closed	-$18.6M	–	1372
2019 Q2	$18.6M	Buy	2,949,979 +201,393	+7%	+$1.21M	0.1%	115
2019 Q1	$15.3M	Buy	+2,748,586	New	+$16.7M	0.09%	125
2018 Q2	–	Sell	-5,000	Closed	-$42K	–	1394
2018 Q1	$42K	Hold	5,000	–	–	﹤0.01%	982
2017 Q4	$49K	Hold	5,000	–	–	﹤0.01%	1007
2017 Q3	$61K	Hold	5,000	–	–	﹤0.01%	914
2017 Q2	$82K	Buy	+5,000	New	+$77.4K	﹤0.01%	845
2014 Q4	–	Sell	-41	Closed	–	–	1505
2014 Q3	$0	Buy	+41	New	+$438	﹤0.01%	1458

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Manhattan's LXRX Position: Q4 2021 in Review

First Manhattan sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2021, closing a stake of 1,079 shares — an estimated $5K sold.

First Manhattan first reported a position in LXRX in Q3 2014 and held it in 9 quarters. The position peaked at $18.6M in Q2 2019. 110 funds tracked by Wall St. Rank hold LXRX as of Q4 2021.

First Manhattan reported no remaining Lexicon Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
First Manhattan sold 1,079 Lexicon Pharmaceuticals shares in Q4 2021, an estimated $5K.
First Manhattan first reported a position in Lexicon Pharmaceuticals in Q3 2014 and held it in 9 quarters.
First Manhattan's Lexicon Pharmaceuticals position peaked at $18.6M in Q2 2019.
110 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2021.

Based on First Manhattan's 13F filing for Q4 2021, filed 14 Feb 2022.